These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28727741)

  • 21. Treatment of Gram-positive infections in critically ill patients.
    Vazquez-Guillamet C; Kollef MH
    BMC Infect Dis; 2014 Nov; 14():92. PubMed ID: 25431211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of vancomycin-resistant enterococci in the United Arab Emirates: a retrospective analysis of 12 years of national AMR surveillance data.
    Thomsen J; Abdulrazzak NM; AlRand H; ; Menezes GA; Moubareck CA; Everett DB; Senok A; Podbielski A
    Front Public Health; 2023; 11():1275778. PubMed ID: 38089023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit.
    Smith RL; Evans HL; Chong TW; McElearney ST; Hedrick TL; Swenson BR; Scheld WM; Pruett TL; Sawyer RG
    Surg Infect (Larchmt); 2008 Aug; 9(4):423-31. PubMed ID: 18759679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial resistance prevalence in bloodstream infection in 29 European countries by age and sex: An observational study.
    Waterlow NR; Cooper BS; Robotham JV; Knight GM
    PLoS Med; 2024 Mar; 21(3):e1004301. PubMed ID: 38484006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. National surveillance of antimicrobial resistance among Gram-positive bacteria in Saudi Arabia.
    Shibl AM; Memish ZA; Kambal AM; Ohaly YA; Ishaq A; Senok AC; Livermore DM
    J Chemother; 2014 Feb; 26(1):13-8. PubMed ID: 24091308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe.
    Hassoun-Kheir N; Guedes M; Ngo Nsoga MT; Argante L; Arieti F; Gladstone BP; Kingston R; Naylor NR; Pezzani MD; Pouwels KB; Robotham JV; Rodríguez-Baño J; Tacconelli E; Vella V; Harbarth S; de Kraker MEA;
    Clin Microbiol Infect; 2024 Mar; 30 Suppl 1():S14-S25. PubMed ID: 37802750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bacterial susceptibility in bloodstream infections: Results from China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2015-2016.
    Zhang F; Li Y; Lv Y; Zheng B; Xue F
    J Glob Antimicrob Resist; 2019 Jun; 17():276-282. PubMed ID: 30611932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective Treatment of Skin Wounds Co-Infected with Multidrug-Resistant Bacteria with a Novel Nanoemulsion.
    Chen J; Cao Z; Cannon J; Fan Y; Baker JR; Wang SH
    Microbiol Spectr; 2022 Apr; 10(2):e0250621. PubMed ID: 35412373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo.
    Parmar A; Lakshminarayanan R; Iyer A; Mayandi V; Leng Goh ET; Lloyd DG; Chalasani MLS; Verma NK; Prior SH; Beuerman RW; Madder A; Taylor EJ; Singh I
    J Med Chem; 2018 Mar; 61(5):2009-2017. PubMed ID: 29363971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oritavancin: a long-acting antibacterial lipoglycopeptide.
    Kaasch AJ; Seifert H
    Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial resistance in gram-positive bacteria.
    Rice LB
    Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
    Crotty MP; Krekel T; Burnham CA; Ritchie DJ
    J Clin Microbiol; 2016 Sep; 54(9):2225-32. PubMed ID: 26962092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
    Carvalhaes CG; Sader HS; Streit JM; Castanheira M; Mendes RE
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0166721. PubMed ID: 34807761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
    Zhanel GG; DeCorby M; Laing N; Weshnoweski B; Vashisht R; Tailor F; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; McCracken M; Mulvey MR; Johnson J; ; Hoban DJ
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1430-7. PubMed ID: 18285482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
    Rybak JM; Marx K; Martin CA
    Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-level analysis of incident vancomycin-resistant enterococci colonization and antibiotic days of therapy.
    McKINNELL JA; Kunz DF; Moser SA; Vangala S; Tseng CH; Shapiro M; Miller LG
    Epidemiol Infect; 2016 Jun; 144(8):1748-55. PubMed ID: 27125574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in antimicrobial resistance in Israel, 2014-2017.
    Dickstein Y; Temkin E; Ish Shalom M; Schwartz D; Carmeli Y; Schwaber MJ
    Antimicrob Resist Infect Control; 2019; 8():96. PubMed ID: 31171967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving efficiency in active surveillance for methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus at hospital admission.
    Morgan DJ; Day HR; Furuno JP; Young A; Johnson JK; Bradham DD; Perencevich EN
    Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1230-5. PubMed ID: 21028966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.